Cohance Lifesciences Limited (NSE:COHANCE)
India · Delayed Price · Currency is INR 439.55
-5.75 (-1.29%)
Sep 11, 2026, 3:30 PM IST
Cohance Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 21,415 | 22,686 | 26,085 | 10,514 | 13,403 | 13,202 |
| 21,415 | 22,686 | 26,085 | 10,514 | 13,403 | 13,202 | |
Revenue Growth | 70.12% | -13.03% | 148.11% | -21.56% | 1.52% | 30.75% |
Cost of Revenue | 6,348 | 8,043 | 9,430 | 3,716 | 5,882 | 5,741 |
Gross Profit | 15,067 | 14,643 | 16,655 | 6,797 | 7,521 | 7,461 |
Selling, General & Admin | 5,074 | 5,261 | 4,601 | 1,396 | 1,218 | 1,024 |
Research & Development | - | - | - | - | - | 103.55 |
Other Operating Expenses | 6,832 | 5,095 | 3,779 | 1,311 | 561.82 | 526.62 |
Operating Expenses | 13,823 | 12,230 | 10,049 | 3,253 | 2,259 | 2,045 |
Operating Income | 1,244 | 2,413 | 6,606 | 3,544 | 5,262 | 5,416 |
Interest Expense | -338 | -372.4 | -410.6 | -74.5 | -128.11 | -62.31 |
Interest & Investment Income | - | 27.3 | 20.7 | 19.3 | 58.32 | 0.69 |
Earnings From Equity Investments | - | - | - | - | - | 411.12 |
Currency Exchange Gain (Loss) | - | 55.2 | 183.1 | 81.2 | 214.38 | 164.21 |
Other Non Operating Income (Expenses) | 321.7 | 49 | 59.3 | 66.8 | 32.9 | 0.02 |
EBT Excluding Unusual Items | 1,228 | 2,172 | 6,459 | 3,637 | 5,439 | 5,930 |
Merger & Restructuring Charges | - | -10.1 | -302.6 | -31.1 | - | - |
Gain (Loss) on Sale of Investments | - | 191.8 | 409.6 | 449.1 | 156.87 | 636.14 |
Gain (Loss) on Sale of Assets | - | 16.2 | -0.2 | -0.7 | -0.07 | 106.03 |
Other Unusual Items | -213.7 | -299.8 | -139.3 | 2.7 | 1.17 | 3.73 |
Pretax Income | 1,014 | 2,070 | 6,426 | 4,057 | 5,597 | 6,676 |
Income Tax Expense | 428.8 | 569.2 | 1,584 | 1,054 | 1,484 | 2,138 |
Earnings From Continuing Operations | 585.3 | 1,501 | 4,842 | 3,003 | 4,113 | 4,538 |
Minority Interest in Earnings | 477 | 291.1 | 31 | - | - | - |
Net Income | 1,062 | 1,792 | 4,873 | 3,003 | 4,113 | 4,538 |
Net Income to Common | 1,062 | 1,792 | 4,873 | 3,003 | 4,113 | 4,538 |
Net Income Growth | -55.99% | -63.22% | 62.30% | -26.99% | -9.37% | 25.24% |
Shares Outstanding (Basic) | - | 382 | 381 | 255 | 255 | 255 |
Shares Outstanding (Diluted) | - | 383 | 384 | 255 | 255 | 255 |
Shares Change | - | -0.21% | 50.73% | - | - | - |
EPS (Basic) | - | 4.69 | 12.79 | 11.80 | 16.16 | 17.83 |
EPS (Diluted) | - | 4.68 | 12.68 | 11.80 | 16.16 | 17.83 |
EPS Growth | - | -63.10% | 7.53% | -26.99% | -9.37% | 25.27% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 1,484 | 3,566 | 3,329 | 1,713 | 2,548 |
Free Cash Flow Per Share | - | 3.88 | 9.29 | 13.08 | 6.73 | 10.01 |
Dividend Per Share | - | - | - | - | 3.000 | 2.000 |
Dividend Growth | - | - | - | - | 50.00% | 0% |
Gross Margin | 70.36% | 64.55% | 63.85% | 64.65% | 56.11% | 56.51% |
Operating Margin | 5.81% | 10.64% | 25.33% | 33.71% | 39.26% | 41.02% |
Profit Margin | 4.96% | 7.90% | 18.68% | 28.56% | 30.69% | 34.37% |
Free Cash Flow Margin | - | 6.54% | 13.67% | 31.66% | 12.78% | 19.30% |
EBITDA | 3,169 | 3,910 | 8,030 | 4,090 | 5,726 | 5,795 |
EBITDA Margin | 14.80% | 17.24% | 30.79% | 38.90% | 42.72% | 43.89% |
D&A For EBITDA | 1,925 | 1,497 | 1,424 | 546 | 464.6 | 378.64 |
EBIT | 1,244 | 2,413 | 6,606 | 3,544 | 5,262 | 5,416 |
EBIT Margin | 5.81% | 10.64% | 25.33% | 33.71% | 39.26% | 41.02% |
Effective Tax Rate | 42.28% | 27.49% | 24.65% | 25.98% | 26.52% | 32.02% |
Revenue as Reported | 21,737 | 23,026 | 26,777 | 11,133 | 13,867 | 14,126 |
Advertising Expenses | - | 161.4 | 97.7 | 34.8 | 34.89 | 18.83 |